Do CBD Gummies Show up on Drug Tests?

BD can be an excellent way to enhance wellness, promote well-being, and encourage relaxation. CBD lovers worldwide often enjoy many potential benefits. They may consume various forms of CBD throughout their day. One of the most innovative ways users get their boost of CBD is from gummies. CBD gummies are delectable treats that have a burst of CBD. Many consumers enjoy taking this snack on the go or for sharing with friends.

However, there are still ongoing discussions surrounding CBD’s status, both federally and within states. Due to this issue, it’s understandable that consumers may feel some trepidation. This is especially true when it comes to blood work for employment. Many users may want to know, “Will I have a CBD positive drug test?”

CBD in drug tests may not have a straightforward answer. It may depend on a few factors, including quality. This article will go over these factors and highlight some critical aspects regarding CBD and hemp. We’ll also delve into how high-quality hemp and CBD gummies for sale can make a difference.
What Is CBD?

Before launching into a detailed explanation, the best starting point may include an examination of CBD. CBD or cannabidiol is a substance that growers can harvest from hemp. Unlike marijuana, CBD derived from hemp has minimal THC or tetrahydrocannabinol. Researchers and users alike have cited THC as having intoxicating effects, including intense drowsiness, lethargy, and paranoia.

Studies show that CBD may not induce the physiological reactions often associated with marijuana. In addition to its non-intoxicating nature, CBD may have other potential benefits. Developing bodies of research indicate that CBD may quell symptoms related to anxiety, sleep deprivation, and stress-related syndromes.
Why Worry About Quality?

CBD has become increasingly popular. Consumers can purchase it from a variety of places, including gas stations and other retail outlets. However, the quality of any of these CBD-infused items, including gummies, may be questionable at best. And when it comes to gummies, ensuring that a purchase is premium means buying from a seller that uses industrial hemp. This is especially important for drug tests.

Some may wonder just how industrial hemp relates to drug testing. Well, most drug tests screen for certain drugs and other substances, and this includes THC. Low-quality or subpar hemp may contain a higher level of THC than American industrial hemp. Products derived from industrial hemp, including CBD-infused gummies, typically have minimal amounts of THC.

This translates into a test that won’t indicate THC use. In fact, researchers recently found that a threshold of 15ng/ml of THC is sufficient for a positive urine sample. Most high-grade CBD items from industrial hemp have 0.3% or less THC. And it’s not only where hemp comes from that counts. Extraction methods are essential, as well. When CBD comes from top-notch extraction procedures such as natural CO2, growers can harvest a higher grade of CBD.

Companies that take CBD seriously source their CBD from American farms that adhere to stringent growing practices. They may also ensure the best ways of getting CBD, including CO2 extraction. The result is a low-THC product with little chance of affecting a drug test.

When shopping around, it’s also important to note that reputable companies will often include detailed lab reports. These reports will contain the amount of CBD, THC, and other substances in a given item.
Getting Your Gummies: PureKana Online

Gummies can be an excellent source of CBD. They are transportable, easy to share, and can satisfy a sweet tooth. CBD fans looking for this tasty treat can buy them in a variety of places and cities. Online CBD gummy sellers abound, but not every company is reputable and sources from high-grade hemp.

A company like Purekana offers top of the line gummies with premium ingredients. PureKana’s gummies boast up to 25mg of industrial-hemp derived CBD per serving. Each bottle of their regular or all-vegan gummies features 20 gummies with fruity flavors.

Their gummies also have an added bonus of affordability. They feature price points that won’t bust a budget. And with a responsive customer care team, consumers may find that they have additional security and assistance.

Feb. 21, 2021 12:00 a.m. Marketplace

3 Marijuana Stocks With High Hopes for the Future

Marijuana stocks are enjoying a bit of a renaissance these days. With Joe Biden in the White House and Democrats taking the Senate, bullish investors are hopeful that greener days are ahead. That’s why immediately after Joe Biden’s victory, we saw marijuana stocks gaining a lot of ground.

Nevertheless, some are wondering is whether this is another false dawn. When Canada legalized cannabis on a federal level, many believed it was a watershed moment for the Cannabis industry. Consequently, several investors rushed in, leading to outsized valuations.

After some essential bubble-bursting, companies are now attractively valued. The post-election momentum caused a momentary blip, and more attractive valuations will return soon.


InvestorPlace – Stock Market News, Stock Advice & Trading Tips

But I digress. Picking quality stocks is never an easy task, especially when you are focusing on a sector that is under the hammer. That’s why you need to separate the wheat from the chaff.

On this list, we include companies that have a strong track record of growth. Stocks will always ebb and flow, depending on the news. However, the companies with excellent performance metrics will continue to do well, regardless of the wider industry’s external circumstances.

So, without further ado, here are three marijuana stocks that will push your returns higher:

  • GW Pharmaceuticals (NASDAQ:GWPH)
  • Aphria (NASDAQ:APHA)
  • OrganiGram Holdings (NASDAQ:OGI)

Marijuana Stocks To Buy: GW Pharmaceuticals (GWPH)

marijuana falling out of a prescription container next to a stethoscope

Source: Shutterstock

GWPH stock soared 46% after Jazz Pharmaceuticals(NASDAQ:JAZZ) agreed to a $7.2 billion acquisition of the CBD biopharma in a cash-and-stock deal expected to close in the second quarter.

GW Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, Epidiolex, in a broad range of disease areas.

Epidiolex is a liquid formulation of pure plant-derived cannabidiol used to treat several rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for spasticity treatment due to multiple sclerosis.

GWPH is a very consistent performer, having exceeded analyst expectations in the past six quarters consecutively. It will boost profits of its new parent with double-digit revenue growth of 41% next year.

Valuation is also a plus for this one. Recently, many pure-plays in the cannabis space have skyrocketed on the back of positive news. Valuations are now outsized. However, GWPH stock trades at 13.5 times price-to-sales. Not too bad, considering the recent blockbuster merger.

Aphria (APHA)

An Aphria (APHA) marijuana product

Source: Shutterstock

Aphria does not have exposure to the U.S. CBD or THC markets due to federal prohibition constraints. Nonetheless, now that the Democrats are in power, we can see headway on that end.

Aphria operates through retail and wholesale channels in Canada and internationally. It has operations in over 10 countries outside of Canada and is the main distributor of medical cannabis to Germany.

Although not having a U.S. presence is its main Achilles heel, it does have some exposure in the form of SweetWater, a craft brewery. Aphria closed the acquisition last year.

CEO and Chairman Irwin Simon said the purchase would allow the Canadian licensed producer to build brand awareness in the U.S. ahead of federal legalization.

In the past five years, sales have grown 179.6% on average. Looking ahead, it’s expected that the company will increase sales by 31.5% next year. For all this, if you get shares for just 9.8 times P/S, I’d say it’s a steal.

Marijuana Stocks To Buy: OrganiGram Holdings (OGI)

30 Marijuana Stocks to Buy as the Future Turns Green

Source: Shutterstock

OrganiGram Holdings focuses on producing indoor-growth cannabis for patients and adult recreational consumers and developing overseas business partnerships.

Its brand portfolio includes Edison Reserve, Edison Cannabis Co, ANKR Organics, and Trailblazer.

OrganiGram has disappointed investors with its sluggish revenue growth and cash burn. But analysts are expecting the next year to bring some relief. Sales and EPS are expected to grow 64.1% and 320.0%, leading to a bullish reading. OGI stock is up 77.4% in the last month. But shares are still trading at 11.2 times price-to-earnings.

OGI has outperformed the S&P 500 by 185.1% and its sector by 198.2% in the past five years. That kind of performance is rare, but investors will ideally want some improvement in fundamentals to accompany this. All the data points to the company turning the corner soon. Until then, the general euphoria regarding the sector will continue to drive shares higher.

On the date of publication, Faizan Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Faizan Farooque is a contributing author for and numerous other financial sites. Faizan has several years of experience analyzing the stock market and was a former data journalist at S&P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.

More From InvestorPlace

The post 3 Marijuana Stocks With High Hopes for the Future appeared first on InvestorPlace.